



MHRA

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Ms W van Bentum-Puijk
UNIVERSITY MEDICAL CENTRE UTRECHT
HEIDELBERGLAAN 100,
UTRECHT
NL-3584 CX
NETHERLANDS

20/12/2021

Dear Ms W van Bentum-Puijk,

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference:	CTA 30913/0006/001-0023
Eudract Number:	2015-002340-14
Product:	ceftriaxone, levofloxacin, piperacilin-tazobactam, hydrocortisone, amoxicillin-clavulanate, azithromycin, clarithromycin, moxifloxacin, ceftaroline, hydroxychloroquine, Tocilizumab, Sarilumab, Heparin, Sarilumab unlicensed, Kaletra 80mg/20mg Oral Solution, interferon beta-1a, anakinra, Lopinavir/Ritonavir Mylan, Ascorbic Acid, simvastatin, Ramipril, Lisinopril, Perindopril, Enalapril, Captopril, losartan, Valsartan, Candesartan, Irbesartan, Repagermanium, cysteamine bitartrate
Protocol number:	n/a
Substantial Amendment Code Number:	AM031

NOTICE OF ACCEPTANCE OF AMENDMENT

I am writing to inform you that the Licensing Authority accepts the proposed amendment to your clinical trial authorisation (CTA), received on 17/12/2021.

This amendment may therefore be made.

If applicable, you should ensure your trial details have been updated on the database where you have registered your trial.



You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

You are reminded that from 1 January 2022 you will need to comply with the requirements specified in the following guidance, where applicable:

o Import of IMPs from listed countries to GB:

<https://www.gov.uk/government/publications/importing-investigational-medicinal-products-into-great-britain-from-approved-countries>

o Supply of IMPs to Northern Ireland:

<https://www.gov.uk/guidance/supplying-investigational-medicinal-products-to-northern-ireland>

o Substantial amendments to clinical trials:

<https://www.gov.uk/guidance/guidance-on-substantial-amendments-to-a-clinical-trial>

Any required substantial amendment to your Clinical Trial Authorisation should be submitted and approved as soon as possible and before 1 January 2022.

Yours sincerely,

**Clinical Trials Unit
MHRA**